IQVIA Named Real World Evidence Leader
Biopharma companies pick IQVIA as the leader in real world data and evidence services in new Life Science Strategy Group report
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE:IQV) today announced that a new Life Science Strategy Group (LSSG) report named IQVIA the market leader in real world data and real world evidence services. One hundred biopharma companies involved in drug development and commercialization participated in this latest LSSG survey. Respondents overwhelmingly chose IQVIA as the thought leader and expert across real world data, real world data analytical capabilities, and real world evidence generation. According to the study, IQVIA was selected due to its track record, breadth of capabilities, deep expertise, and robust data.
“We are delighted with the industry’s recognition of IQVIA as the leader in real world capabilities as we enable clients to reimagine possibilities and discover novel ways to improve patient outcomes,” said Rob Kotchie, president, Real World Solutions at IQVIA. “Real world evidence is transforming healthcare and we are excited to be leading this transformation, and we are committed to investing in emerging areas such as genomics and external comparators to improve evidence generation with the goal of improving outcomes. IQVIA remains equally committed to thoughtful, innovative approaches to the responsible uses of non-identified healthcare information for research purposes and the protection of privacy.”
Powered by the IQVIA CORETM, IQVIA leverages its healthcare expertise, data, analytics and technology to generate meaningful insights. One respondent, a senior director of a medium-sized biopharma company in North America, said, “IQVIA has the ability to integrate multiple data sources…They also can marry therapeutic area experts with data and bioinformatics experts.”
Life Science Strategy Group, LLC is a consultancy specializing in new product planning and commercialization strategy for a variety of life science markets. The report, Real World Evidence – A Market at an Inflection Point and Its Impact on the CRO Industry, analyzed the opinions of senior decision-makers from small, medium and large biopharmaceutical companies in North America and Europe to support development and commercial activities and trends, identify perceived market leaders and explore implications for the future of the contract research organization industry.
For more information about the Life Science Strategy Group report, visit our web site.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 61,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.busc2.com.